* indicates a required field
2023 Call for Abstracts and Applications
Share your knowledge with orthopaedic surgeons from around the world at the 2023 OTA Annual Meeting, October 18-21, 2023 in Seattle, Washington. The deadline for submissions is February 10, 2023 at 5:00 PM CST .
SUBMISSION CATEGORIES
Podium: Podium presentations are six minutes in length. There is not a separate submission form for posters. The OTA Program Committee will determine the most effective presentation method, either podium or poster.
Breakout: One main topic with a moderator and 3 to 4 faculty. Open to questions from the audience. This includes case presentations. Concurrent breakout sessions are held throughout the meeting — 60 min in length.
Main Symposium: One main topic with a moderator and 3 to 5 faculty. Leave a minimum of 10 minutes for discussion and questions at the end of the session. This is held in the general session room with no conflicting sessions — up to 75 min in length.
Late Breaking: Abstracts with primary outcome data that are not available at the time of abstract submission. Submitted abstracts will need to include sufficient data for the committee to judge the scientific rigor and magnitude of the research (i.e., demographic data, study interventions, study outcome, follow-up rates, etc.). If accepted, authors will need to provide the Program Committee Chairs an unblinded abstract by August 1, and the full manuscript at the standard September deadline. There will be no exceptions.
The Late Breaking category is reserved for high-impact papers, typically multicenter studies with large sample sizes, that are likely to be published in major medical journals and would not be eligible for presentation at the following OTA meeting.
New Techniques and Emerging Evidence: Abstracts submitted to this category address a clinical innovation of interest to the membership, not yet at a level of evidence that supports its inclusion as a typical podium submission. These abstracts may address a clinical problem that requires a more efficient solution, a new technique, or a new implant supported by early clinical data.
This category is not designed to serve as an advertisement for a particular commercial product, so please avoid commercial bias. You cannot submit your abstract to both this category and the podium category. You must choose one category.
Presentation details will be provided if accepted.
FINANCIAL CONFLICT OF INTEREST DISCLOSURES: Complete author disclosures will be required and collected within the abstract submission portal for the presenting author / faculty and corresponding author / moderator if different from presenting author at the time of submission. Disclosures must be dated October 19, 2022, or later. Any disclosures made before this date will not be valid. If the abstract is accepted, the corresponding author will be responsible for collecting and submitting all co-author and group author disclosures.
IMPORTANT DATES
Abstract Guidelines
FAQs
QUESTIONS: Contact the OTA office at ota@ota.org with any questions.
SUBMISSION CATEGORIES
Podium: Podium presentations are six minutes in length. There is not a separate submission form for posters. The OTA Program Committee will determine the most effective presentation method, either podium or poster.
Breakout: One main topic with a moderator and 3 to 4 faculty. Open to questions from the audience. This includes case presentations. Concurrent breakout sessions are held throughout the meeting — 60 min in length.
Main Symposium: One main topic with a moderator and 3 to 5 faculty. Leave a minimum of 10 minutes for discussion and questions at the end of the session. This is held in the general session room with no conflicting sessions — up to 75 min in length.
Late Breaking: Abstracts with primary outcome data that are not available at the time of abstract submission. Submitted abstracts will need to include sufficient data for the committee to judge the scientific rigor and magnitude of the research (i.e., demographic data, study interventions, study outcome, follow-up rates, etc.). If accepted, authors will need to provide the Program Committee Chairs an unblinded abstract by August 1, and the full manuscript at the standard September deadline. There will be no exceptions.
The Late Breaking category is reserved for high-impact papers, typically multicenter studies with large sample sizes, that are likely to be published in major medical journals and would not be eligible for presentation at the following OTA meeting.
New Techniques and Emerging Evidence: Abstracts submitted to this category address a clinical innovation of interest to the membership, not yet at a level of evidence that supports its inclusion as a typical podium submission. These abstracts may address a clinical problem that requires a more efficient solution, a new technique, or a new implant supported by early clinical data.
This category is not designed to serve as an advertisement for a particular commercial product, so please avoid commercial bias. You cannot submit your abstract to both this category and the podium category. You must choose one category.
Presentation details will be provided if accepted.
FINANCIAL CONFLICT OF INTEREST DISCLOSURES: Complete author disclosures will be required and collected within the abstract submission portal for the presenting author / faculty and corresponding author / moderator if different from presenting author at the time of submission. Disclosures must be dated October 19, 2022, or later. Any disclosures made before this date will not be valid. If the abstract is accepted, the corresponding author will be responsible for collecting and submitting all co-author and group author disclosures.
IMPORTANT DATES
February 10, 2023 5:00 PM CST
|
Abstract Submission Closes
|
Late-May 2023
|
Accepted / Declined Notifications Sent
|
Early June 2023
|
Co-author disclosures required for accepted abstracts
|
June 2023
|
Annual Meeting Registration Opens
|
August 1, 2023
|
Late Breaking unblinded abstract due
|
Abstract Guidelines
FAQs
QUESTIONS: Contact the OTA office at ota@ota.org with any questions.